← Back to Search

SMART Interventions for Opioid Use Disorder

N/A
Waitlist Available
Research Sponsored by Karen Derefinko, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 8 months
Awards & highlights

Study Summary

This trial will compare the effectiveness of two different interventions for helping people stick to their medication-assisted treatment for substance abuse.

Who is the study for?
This trial is for adults with Opioid Use Disorder who are eligible to receive buprenorphine-naloxone medication, as determined by the study doctor. Participants must have access to a telephone and be able to understand spoken English.Check my eligibility
What is being tested?
The SMART Trial is testing two interventions aimed at improving adherence to medication-assisted treatment: Contingency Management (CM), which rewards patients for meeting certain goals, and a combination of Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM).See study design
What are the potential side effects?
While specific side effects are not listed for the interventions being tested in this trial, common side effects associated with buprenorphine-naloxone include nausea, headache, dizziness, drowsiness, constipation, and sweating.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 8 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 8 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Medication-Assisted Treatment (MAT) Adherence

Trial Design

3Treatment groups
Active Control
Group I: Contingency Management (CM)Active Control1 Intervention
CM is a behavioral method that employs external rewards for target behavior. Participants will receive gift cards for adhering to treatment (attending physician visits and being adherent to buprenorphine-naloxone) for their first 4 clinic visits.
Group II: Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM)Active Control1 Intervention
Participants will receive the BSM intervention at 4 timepoints.
Group III: BSM+CMActive Control2 Interventions
BSM+CM is a combination of the two other arms. Participants may be randomized to this arm only in stage 2 of the SMART design.

Find a Location

Who is running the clinical trial?

Karen Derefinko, PhDLead Sponsor
3 Previous Clinical Trials
367 Total Patients Enrolled
University of MemphisOTHER
71 Previous Clinical Trials
11,689 Total Patients Enrolled
University of New MexicoOTHER
374 Previous Clinical Trials
3,528,360 Total Patients Enrolled

Media Library

Brief Motivational Intervention plus Substance Free Activities Session Clinical Trial Eligibility Overview. Trial Name: NCT04080180 — N/A
Opioid Use Disorder Research Study Groups: Contingency Management (CM), Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM), BSM+CM
Opioid Use Disorder Clinical Trial 2023: Brief Motivational Intervention plus Substance Free Activities Session Highlights & Side Effects. Trial Name: NCT04080180 — N/A
Brief Motivational Intervention plus Substance Free Activities Session 2023 Treatment Timeline for Medical Study. Trial Name: NCT04080180 — N/A
~91 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top